Efficancy and safety of dosage adjustments for linezolid in patients with renal impairment

Efficancy and safety of dosage adjustments for linezolid in patients with renal impairment - dosage adjustments for linezolid

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000028437

Enrollment

Registered

2017-10-01

Start date

2017-10-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infectious disease

Interventions

linezolid dose adjustment on Therapeutic Drug Monitoring

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients after providing informed consent received linezolid from October 2017 to December 2021 at Kitasato University Hospital (Kanagawa,Japan).

Exclusion criteria

Exclusion criteria: 1)allergy to linezolid 2)disseminated intravascular coagulation 3)thrombocytopenia before linezolid treatment

Design outcomes

Primary

Measure	Time frame
assessment of thrombocytopenia	—

Countries

Japan

Contacts

Public ContactToshiaki Komatsu

Kitasato University Hospital Department of Pharmacy

t.komatu@kitasato-u.ac.jp(+81)42-778-8111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026